Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics, Incorporated

RBC Capital analyst Leonid Timashev maintained a Buy rating on Cytokinetics yesterday and set a price target of $112.00. Timashev covers the Health...

RBC Capital Keeps Their Buy Rating on Cytokinetics (CYTK)

Analysts fell to the sidelines weighing in on Cytokinetics (CYTK) and Becton Dickinson (BDX) with neutral ratings, indicating that the experts are ...

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Becton Dickinson (BDX)

In a report released on August 28, Leonid Timashev from RBC Capital maintained a Buy rating on Cytokinetics, with a price target of $112.00. The co...

RBC Capital Sticks to Their Buy Rating for Cytokinetics (CYTK)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK) and Ibio (IBIO) with bullish sen...

Wall Street Analysts Are Bullish on Top Healthcare Picks

The latest announcement is out from Cytokinetics ( ($CYTK) ). On August 28, 2026, Cytokinetics reported positive primary results from its pivotal P...

Cytokinetics Reports Positive Phase 3 Aficamten HCM Results

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK), SELLAS Life Sciences Group (SLS...

Cytokinetics ( ($CYTK) ) has issued an announcement. On August 13, 2026, Cytokinetics filed a complaint in the U.S. District Court for the District...

Cytokinetics Files Patent Suit to Protect MYQORZO Franchise

J.P. Morgan analyst Tessa Romero maintained a Buy rating on Cytokinetics today and set a price target of $103.00. Romero covers the Healthcare sect...

J.P. Morgan Keeps Their Buy Rating on Cytokinetics (CYTK)

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Cytokinetics on August 11 and set a price target of $112.00. The company’s...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CYTK	$76.10	+4.65%	714.48K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CYTK	$76.10	+4.6%	714.48K
3
4
5
6

CYTK

Get Cytokinetics, Incorporated Data in Excel

Get Cytokinetics, Incorporated Data in Excel